PUMA BIOTECHNOLOGY, INC.
PUMA BIOTECHNOLOGY, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
PUMA BIOTECHNOLOGY, INC. generates cash from operations, so a burn-based runway figure does not apply.
Across 35 concluded trials, 91% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 5, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| October 30, 2027 | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | Trial Milestone | Phase 2 |
| December 30, 2027 | A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | Trial Milestone | Phase 2 |
| March 31, 2028 | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) | Trial Milestone | Phase 2 |
Track PBYI alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open PBYI in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.